Cleo's Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark
Highlights
A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers”
The study confirmed that CLEO’s initial test for the surgical triage market:
– Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;
– Correctly detected 90% of early-stage cancers compared to only 50% using standard
workflows; and– Can be easily adopted for use into clinical practice.
The superior performance of CLEO’s test now compared to all current routine
clinical tools shows the significant global potential for the test in clinical decision
making prior to surgical intervention.
MELBOURNE, AUSTRALIA, 29 May 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of a milestone article on its blood test for the accurate and early detection of ovarian cancer.
The article, entitled ‘Utility of a Multi-Marker Panel with Ultrasound for Enhanced Classification of Adnexal Mass’ was published in peer reviewed medical journal, “Cancers”.
A copy of the publication is available here: See Link
CLEO’s Blood Test Far Superior to Current Standard of Care The benchmarking study compared CLEO’s ovarian cancer blood test against the current standard clinical workflows that use CA125 and ultrasound to predict malignancy. The outcomes of the study build on previous results (see ASX Announcements 6 November 2023, and 25 March 2024) which clearly demonstrate that CLEO’s ovarian cancer blood test is far superior to all routine clinical tools used by doctors to ‘predict’ the diagnosis of an adnexal mass prior to surgery.
Importantly, CLEO’s test correctly detected 90% of early-stage cancers compared to only 50% using current standard of care workflows of CA125 and ultrasound.
Commenting on the latest study data, CLEO Chief Executive,
Richard Allman, said:
“Our peer-reviewed publication strategy is delivering gold-standard clinical evidence which is vitally important as we begin to engage with potential early adopters of our technology.
Having demonstrated now that the CLEO ovarian cancer blood test is far superior to CA125 and ultrasound in our initial pre-surgical triage market, we open up new dialogue with physicians to consider the potential material benefits that CLEO brings for their patients.
More broadly, these encouraging results on early-stage cancer detection provide impetus for us to progress the development of CLEO’s screening test for ovarian cancer.